When leukemia, lymphoma, or multiple myeloma returns after initial treatment, specialized salvage pathways, chemotherapy, CAR-T cell therapy, and allogeneic transplant, offer renewed hope. Eligibility for each depends on relapse timing, disease biology, and patient fitness rather than institutional preference. Key Takeaways Salvage chemotherapy re-establishes disease control for chemo-sensitive relapses before high-intensity options like transplant India's indigenous NexCAR19

When blood cancer returns after remission, patients and families face critical decisions about next-step therapies. India's oncology landscape now offers salvage chemotherapy, targeted agents, CAR-T immunotherapy, and stem cell transplants across a tiered network of public and private centers [2]. Key Takeaways Four core pathways, salvage chemotherapy, targeted therapy, CAR-T cell therapy, and allogeneic transplant, are available for relapsed blood cancer patients in India [3